Zusammenfassung
Die Behandlung von Persönlichkeits- und Verhaltensstörungen ist zur Domäne der Psychotherapie geworden. Gleichwohl hat die Psychopharmakotherapie insbesondere im Klinikalltag einen hohen Stellenwert. Einige Verhaltensstörungen werden aufgrund der neuen DSM-5- und ICD11-Strukturen in anderen Kapiteln besprochen, z. B. die Verhaltenssüchte in Kapitel 7.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Ballester-Arnal R, Castro-Calvo J, Giménez-García C et al (2020) Psychiatric comorbidity in compulsive sexual behavior disorder (CSBD). Addict Behav 107:106384
Bellino S, Bozzatello P, Rocca G et al (2014) Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol 28:125–132
Black DW, Zanarini MC, Romine A et al (2014) Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 171:1174–1182
Bozzatello P, Brignolo E, De Grandi E, Bellino S (2016) Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med 5(8):E67
Bozzatello P, Rocca P, Bellino S (2018) Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: a follow-up study. Clin Drug Investig 38(4):367–372
Bridler R, Häberle A, Müller ST et al (2015) Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol 25:763–772
Costa AM, Medeiros GC, Redden S et al (2018) Cognitive-behavioral group therapy for intermittent explosive disorder: description and preliminary analysis. Rev Bras Psiquiatr 40(3):316–319
Crawford MJ, Sanatinia R, Barrett B et al (2018) The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry 175(8):756–764
Cristea IA, Gentili C, Cotet CD et al (2017) Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry 74(4):319–328
DGPPN (Hrsg) (2022) für die Leitliniengruppe: S3-Leitlinie Borderline-Persönlichkeitsstörung. Version 1.0 vom 14.11.2022. https://register.awmf.org/assets/guidelines/038-015l_S3_Borderline-Persoenlichkeitsstörungen_2022-11.pdf. Zugegriffen: 30. Mai 2023
Gunderson JG, Herpertz SC, Skodol AE et al (2018) Borderline personality disorder. Nat Rev Dis Primers 4:18029
Hancock-Johnson E, Griffiths C, Picchioni M (2017) A focused systematic review of pharmacological treatment for borderline personality disorder. CNS Drugs 31(5):345–356
Herpertz SC (2018) Neue Wege der Klassifikation von Persönlichkeitsstörungen in ICD-11. Fortschr Neurol Psychiatr 86(03):150–155
Hill N, Geoghegan M, Shawe-Taylor M (2016) Evaluating the outcomes of the STEPPS programme in a UK community-based population; implications for the multidisciplinary treatment of borderline personality disorder. J Psychiatr Ment Health Nurs 23:347–356
Ingenhoven T, Lafay P, Rinne T et al (2010) Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry 71:14–25
Ingenhoven TJ, Duivenvoorden HJ (2011) Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol 31(4):489–496
Jeung-Maarse H, Schmitgen MM, Schmitt R et al (2023) Oxytocin effects on amygdala reactivity to angry faces in males and females with antisocial personality disorder. Neuropsychopharmacology 48(6):946–953
Krüger TH, Magid M, Wollmer MA (2016) Can botulinum toxin help patients with borderline personality disorder? Am J Psychiatry 173(9):940–941
Kulkarni J, Thomas N, Hudaib AR et al (2018) Effect of the glutamate NMDA receptor antagonist memantine as adjunctive treatment in borderline personality disorder: an exploratory, randomised, double-blind, placebo-controlled trial. CNS Drugs 32(2):179–187
Lieslehto J, Tiihonen J, Lähteenvuo M et al (2023) Association of pharmacological treatments and real-world outcomes in borderline personality disorder. Acta Psychiatr Scand 147(6):603–613
Lischke A, Herpertz SC, Berger C (2017) Divergent effects of oxytocin on (para-)limbic reactivity to emotional and neutral scenes in females with and without borderline personality disorder. Soc Cogn Affect Neurosci 12(11):1783–1792
Martín-Blanco A, Patrizi B, Soler J et al (2017a) Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report. Int Clin Psychopharmacol 32(4):231–234
Martín-Blanco A, Ancochea A, Soler J et al (2017b) Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatr Scand 136(3):323–331
McCabe GA, Widiger TA (2020) A comprehensive comparison of the ICD-11 and DSM-5 section III personality disorder models. Psychol Assess 32:72–84
Mielke EL, Neukel C, Bertsch K et al (2018) Alterations of brain volumes in women with early life maltreatment and their associations with oxytocin. Horm Behav 97:128–136
Naguy A, Al-Enezi N (2019) Lamotrigine uses in psychiatric practice. Am J Ther 6(1):e96–e102
Pérez-Pérez B, Cristóbal-Narváez P, Sheinbaum T et al (2018) Interaction between FKBP5 variability and recent life events in the anxiety spectrum: evidence for the differential susceptibility model. PLoS ONE 13(2):e193044
Simonsen S, Bateman A, Bohus M et al (2019) European guidelines for personality disorders: past, present and future. Borderline Personal Disord Emot Dysregul 6:9
Stoffers J, Völlm BA, Rücker G et al (2010) Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 6:CD5653
Stoffers-Winterling J, Lieb K (2015) Pharmakotherapie von Borderline-Persönlichkeitsstörungen – Versorgungsalltag versus aktuelle externe Evidenz. Info Neurol Psychiatr 17:51–55
Stoffers-Winterling JM, Storebø OJ, Pereira Ribeiro J et al (2022) Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 11(11):CD12956
Storebø OJ, Stoffers-Winterling JM, Völlm BA et al (2020) Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 5(5):CD12955
Tebartz van Elst L, Fleck M, Bartels S et al (2016) Increased prevalence of intermittent rhythmic delta or theta activity (IRDA/IRTA) in the electroencephalograms (EEGs) of patients with borderline personality disorder. Front Behav Neurosci 10:12
Timäus C, Meiser M, Bandelow B et al (2019) Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. BMC Psychiatry 19:393
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Müller, M.J., Benkert, O. (2023). Medikamente zur Behandlung von Persönlichkeits- und Verhaltensstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-67685-1_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-67684-4
Online ISBN: 978-3-662-67685-1
eBook Packages: Medicine (German Language)